Home
About
- Overview
- Team
- Investors
Science
Pipeline
Partners
News & Events
Contact
Menu Menu

A British mitochondrial startup wants to break ground in ALS and Parkinson’s. It has £50M to try

8 September 2025

Endpoints News

https://www.nrgtherapeutics.com/wp-content/uploads/2026/08/Neil_Miller_CEO_NRG_Therapeutics_-_in_lab.webp 900 1600 Webadm https://www.nrgtherapeutics.com/wp-content/uploads/2026/07/NRG_Logo.png Webadm2025-09-08 08:00:342026-08-14 14:16:22A British mitochondrial startup wants to break ground in ALS and Parkinson’s. It has £50M to try

© NRG Therapeutics

Terms & Conditions
Privacy Policy

NRG Therapeutics Announces Oversubscribed £50m ($67m) Series B Financing to...

Stevenage, UK based NRG Therapeutics raised a $67M series B today to advance...